Stryker (SYK) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
1 Dec, 2025Executive summary
Annual meeting scheduled for May 8, 2025, with virtual participation available for shareholders.
Shareholders are encouraged to review proxy materials and vote by May 7, 2025.
Voting matters and shareholder proposals
Ten directors are up for election, with the board recommending a vote for each nominee.
Ratification of Ernst & Young LLP as independent auditor for 2025 is recommended.
Approval sought for amended and restated 2011 Long-Term Incentive Plan, 2011 Performance Incentive Award Plan, and 2008 Stock Purchase Plan.
Advisory vote on named executive officer compensation is recommended for approval.
Shareholder proposal for increased transparency in political spending is recommended against by the board.
Board of directors and corporate governance
Board includes ten nominees, with roles such as Chair, CEO, President, and Lead Independent Director specified.
Latest events from Stryker
- Definitive additional proxy materials filed for shareholder voting, with no fee required.SYK
Proxy filing23 Mar 2026 - Virtual meeting to elect directors, ratify auditor, and approve pay amid strong 2025 results.SYK
Proxy filing23 Mar 2026 - Strategy targets digital, M&A, and margin gains, with double-digit EPS growth through 2028.SYK
Investor Day 20253 Feb 2026 - Q2 organic sales up 9%, adjusted EPS up 10.6%, and guidance raised on strong demand.SYK
Q2 20242 Feb 2026 - Double-digit growth, record Mako installs, and strong 2026 outlook despite tariff headwinds.SYK
Q4 20252 Feb 2026 - Mako innovation, easing pricing, and new launches drive growth and share gains into 2025.SYK
2024 Wells Fargo Healthcare Conference22 Jan 2026 - Q3 net sales up 11.9% and adjusted EPS up 16.7%, with strong 2024 outlook and M&A momentum.SYK
Q3 202418 Jan 2026 - Double-digit organic growth and margin expansion, with portfolio moves and Spine impairments.SYK
Q4 20249 Jan 2026 - Double-digit sales growth, innovation, and all proposals approved amid leadership transitions.SYK
AGM 20258 Jan 2026 - 2025 targets 8%-9% growth, margin expansion, and innovation through ASC, robotics, and M&A.SYK
Citi’s 2025 Medtech and Life Sciences Access Day7 Jan 2026